{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:15:20Z","timestamp":1773332120926,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,19]],"date-time":"2023-10-19T00:00:00Z","timestamp":1697673600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.htct.2023.09.2362","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T19:12:06Z","timestamp":1698693126000},"page":"434-442","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4750-034X","authenticated-orcid":false,"given":"Elo\u00edsa","family":"Riva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7384-1236","authenticated-orcid":false,"given":"David","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiorella","family":"Villano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-4924","authenticated-orcid":false,"given":"Virginia","family":"Bove","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0001","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient","author":"Mateos","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"5","key":"10.1016\/j.htct.2023.09.2362_bib0002","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"36","key":"10.1016\/j.htct.2023.09.2362_bib0003","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0004","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0005","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/bjh.13532","article-title":"Risks, severity and timing of infections in patients with multiple myeloma: a longitudinal cohort study in the era of immunomodulatory drug therapy","volume":"171","author":"Teh","year":"2015","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7326\/0003-4819-96-1-47","article-title":"Biphasic pattern of bacterial infection in multiple myeloma","volume":"96","author":"Savage","year":"1982","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0007","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12879-016-2155-1","article-title":"Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0008","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ejh.13066","article-title":"Risk factors for blood stream infections in multiple myeloma: a population-based study of 1154 patients in Denmark","volume":"101","author":"S\u00f8rrig","year":"2018","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.htct.2023.09.2362_bib0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.blre.2014.01.004","article-title":"Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection","volume":"28","author":"Teh","year":"2014","journal-title":"Blood Rev"},{"key":"10.1016\/j.htct.2023.09.2362_bib0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ejca.2016.07.025","article-title":"Infection risk with immunomodulatory and proteasome inhibitor\u2013based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis","volume":"67","author":"Teh","year":"2016","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.htct.2023.09.2362_bib0011","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9343(81)90303-X","article-title":"Oken MM. Influence of treatment and response status on infection risk in multiple myeloma","volume":"71","author":"Perri","year":"1981","journal-title":"Am J Med"},{"issue":"290","key":"10.1016\/j.htct.2023.09.2362_bib0012","first-page":"517","article-title":"Perspectives in multiple myeloma: survival, prognostic factors and disease complications in a single centre between 1975 and 1988","volume":"79","author":"Rayner","year":"1991","journal-title":"Q J Med"},{"issue":"6","key":"10.1016\/j.htct.2023.09.2362_bib0013","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.htct.2023.09.2362_bib0014","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.beha.2005.01.013","article-title":"hematologic and infectious complications in multiple myeloma","volume":"18","author":"Blad\u00e9","year":"2005","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1016\/j.htct.2023.09.2362_bib0015","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.htct.2023.09.2362_bib0016","first-page":"234","article-title":"Infections in hospitalised patients with multiple myeloma: main characteristics and risk factors","volume":"32","author":"Valkovic","year":"2015","journal-title":"Turk J Haematol Off J Turk Soc Haematol"},{"issue":"2","key":"10.1016\/j.htct.2023.09.2362_bib0017","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/ejh.12813","article-title":"Epidemiology of bloodstream infections in patients with myeloma receiving current era therapy","volume":"98","author":"Teh","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.htct.2023.09.2362_bib0018","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.blre.2019.01.001","article-title":"Management of infectious complications in multiple myeloma patients: expert panel consensus-based recommendations","volume":"34","author":"Girmenia","year":"2019","journal-title":"Blood Rev"},{"issue":"2","key":"10.1016\/j.htct.2023.09.2362_bib0019","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"30","key":"10.1016\/j.htct.2023.09.2362_bib0020","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1016\/j.vaccine.2020.05.024","article-title":"Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: results of a prospective clinical study","volume":"38","author":"Stoma","year":"2020","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.htct.2023.09.2362_bib0021","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br J Cancer"},{"issue":"29","key":"10.1016\/j.htct.2023.09.2362_bib0022","doi-asserted-by":"crossref","first-page":"4784","DOI":"10.1200\/JCO.2007.14.9641","article-title":"Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study","volume":"26","author":"Chanan-Khan","year":"2008","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0023","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.3324\/haematol.2014.114025","article-title":"Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies","volume":"100","author":"Teh","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.htct.2023.09.2362_bib0024","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00277-019-03621-1","article-title":"The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey","volume":"98","author":"Brioli","year":"2019","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.htct.2023.09.2362_bib0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.clml.2021.02.002","article-title":"Epidemiology and Risks of Infections in Patients With Multiple Myeloma Managed With New Generation Therapies","volume":"21","author":"Lim","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.htct.2023.09.2362_bib0026","article-title":"Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Latin America","volume":"8","author":"Bove","year":"2022","journal-title":"JCO Glob Oncol"},{"issue":"12","key":"10.1016\/j.htct.2023.09.2362_bib0027","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.htct.2023.09.2362_bib0028","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.htct.2023.09.2362_bib0029","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1600-0609.2012.01814.x","article-title":"Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations","volume":"89","author":"Caravita","year":"2012","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12185-010-0735-1","article-title":"Reduced risk of bacterial infection in multiple myeloma patients with VAD regimen without intermittent high-dose dexamethasone","volume":"93","author":"Isoda","year":"2011","journal-title":"Int J Hematol"},{"issue":"17","key":"10.1016\/j.htct.2023.09.2362_bib0031","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/archinte.158.17.1889","article-title":"Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution","volume":"158","author":"Blad\u00e9","year":"1998","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.htct.2023.09.2362_bib0032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.htct.2023.09.2362_bib0033","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3346\/jkms.2016.31.4.510","article-title":"Pretreatment lymphopenia, poor performance status, and early courses of therapy are risk factors for severe bacterial infection in patients with multiple myeloma during treatment with bortezomib-based regimens","volume":"31","author":"Hyun","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.htct.2023.09.2362_bib0034","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2009.03.006","article-title":"Infections in patients with multiple myeloma","volume":"46","author":"Nucci","year":"2009","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1016\/j.htct.2023.09.2362_bib0035","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137923025816?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137923025816?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T17:05:01Z","timestamp":1729271101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137923025816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2531137923025816"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2023.09.2362","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epidemiology and risk factors for the development of infectious complications in newly diagnosed multiple myeloma: a multicenter prospective cohort study in Uruguay","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2023.09.2362","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}